A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases.

Radiat Oncol · 2017 · PMC5402642 · PMID 28438175

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

a strong trendp = 0.059so close (0.05 < p ≤ 0.1)

In a randomized trial of 508 eligible patients, memantine in addition to WBRT (20 mg/d, starting 3 days prior to WBRT for 24 weeks) showed a strong trend towards less decline in delayed recall at 24 weeks when compared to WBRT without memantine ( p = 0.059).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.